Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1Blast Crisis 1

Interventions

Cyclophosphamide 53fludarabine phosphate 52Peripheral Blood Stem Cell Transplantation 52Busulfan 39Tacrolimus 36Mycophenolic Acid 32Methotrexate 31Cyclosporine 31Antilymphocyte Serum 31Filgrastim 26Whole-Body Irradiation 25Cytarabine 24Radiotherapy 21Methylprednisolone 20Cord Blood Stem Cell Transplantation 18Melphalan 17Imatinib Mesylate 17Etoposide 16Flow Cytometry 12Thiotepa 11fludarabine 10Dasatinib 10Therapeutics 9Sirolimus 9Granulocyte Colony-Stimulating Factor 9nilotinib 8sargramostim 7Psychiatric Rehabilitation 7Decitabine 7Prednisone 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Blast Crisis × troxacitabine × Myeloid × Clear all
NCT00012259 2021-06-10

Troxacitabine in Treating Patients With Chronic Myelogenous Leukemia

Takeda

Phase 2 Completed
31 enrolled
MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡